BMY’s Reyataz sales fell 7% YoY, the first such decline in a long time. GILD’s Stribild could already be taking significant share from PI-based regimens.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”